Nov 08, 2023 5:35 pm EST Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
Nov 01, 2023 8:30 am EDT Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
Oct 06, 2023 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 19, 2023 4:01 pm EDT Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
Sep 01, 2023 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 31, 2023 4:01 pm EDT Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
Aug 08, 2023 4:01 pm EDT Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
Aug 04, 2023 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 01, 2023 4:01 pm EDT Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
Jul 31, 2023 4:01 pm EDT Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference